| 1.63 0.04 (2.52%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.42 |
1-year : | 2.83 |
| Resists | First : | 2.07 |
Second : | 2.42 |
| Pivot price | 1.76 |
|||
| Supports | First : | 1.49 |
Second : | 1.12 |
| MAs | MA(5) : | 1.74 |
MA(20) : | 1.69 |
| MA(100) : | 1.67 |
MA(250) : | 1.41 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 44.8 |
D(3) : | 59.3 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 5.69 | Low : | 0.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SXTC ] has closed above bottom band by 32.4%. Bollinger Bands are 22.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.66 - 1.67 | 1.67 - 1.68 |
| Low: | 1.51 - 1.52 | 1.52 - 1.53 |
| Close: | 1.62 - 1.63 | 1.63 - 1.64 |
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
Mon, 22 Sep 2025
Comparing China SXT Pharmaceuticals (NASDAQ:SXTC) and United Therapeutics (NASDAQ:UTHR) - Defense World
Sun, 07 Sep 2025
SXTC Stock Experiences Volatility Amid Industry Shifts and Financial Updates - timothysykes.com
Sun, 07 Sep 2025
SXTC Shares Slide Amid Volatile Market Dynamics - StocksToTrade
Mon, 19 May 2025
SXTC Stock Takes a Hit: What’s Behind the Drop? - StocksToTrade
Tue, 06 May 2025
SXTC Stocks Flying High: Too Late to Buy? - StocksToTrade
Tue, 22 Apr 2025
SXTC Stock Soars: Time to Invest? - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 116 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 35.3 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 73 (K) |
| EPS | -2.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | -189.8 % |
| Operating Margin | -224.1 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -22.5 % |
| Qtrly Rev. Growth | -7.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.01 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.71 |
| PEG Ratio | 0 |
| Price to Book value | 1.45 |
| Price to Sales | 108.69 |
| Price to Cash Flow | -80.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|